亚洲日韩欧美综合-亚洲日韩欧美一区二区在线-亚洲日韩欧美视频-亚洲日韩精品欧美一区二区-国产欧美日韩综合

會員登錄|免費注冊|忘記密碼|管理入口 返回主站||保存桌面|手機瀏覽|聯系方式|購物車
企業會員第1年

武漢康寶泰精細化工有限公司武昌一部  

醫藥中間體,維生素,植物提取物

搜索
新聞中心
  • 暫無新聞
產品分類
  • 暫無分類
聯系方式
  • 聯系人:付經理
  • 電話:027-87738695
  • 郵件:664219562@qq.com
  • 傳真:027-87738652
  • QQ:664219562
站內搜索
 
榮譽資質
  • 暫未上傳
友情鏈接
  • 暫無鏈接
首頁 > 供應產品 > 坎地沙坦酯 CAS號: 145040-37-5
坎地沙坦酯 CAS號: 145040-37-5
單價 1.00 / 千克對比
銷量 暫無
發貨 湖北武漢市付款后3天內
庫存 10000千克起訂1千克
品牌 康寶泰
型號 CAS號: 145040-37-5
規格 25
過期 長期有效
更新 2013-11-28 11:21
 
詳細信息

中文名稱: 坎地沙坦酯
中文同義詞: 2-乙氧基-1-[[2'-(1H-四氮唑-5-基)[1,1'-聯苯基]-4-基]甲基]-1H-苯并咪唑-7-甲酸-1-[[(環己氧基)羰基]氧基]乙酯;坎地沙坦西來替昔酯;坎地沙坦酯;坎地沙坦西酯;坎地沙坦西來替昔酯/2-乙氧基-1-[[2'-(1H-四氮唑-5-基)[1,1'-聯苯基]-4-基]甲基]-1H-苯并咪唑-7-甲酸-1-[[(環己氧基)羰基]氧基]乙酯;CANDESARTAN CILEXETIL 坎地沙坦酯;(±)-1-(環己氧代羰基氧代)乙基-[2-乙氧基-1-[[2'-(1H-四氮唑基-5)聯苯基-4]甲基]-1H-苯并咪唑-7]
英文名稱: Candesartan cilexetil
英文同義詞: CANDESARTAN CILEXITIL;CANDESARTAN CILEXETIL;1-[[(cyclohexyloxy)carbonyl]oxy]ethyl 2-ethoxy-1-[[2'-(1h-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-1h-benzimidazole-7-carboxylate;1-(((cyclohexyloxy)carbonyl)oxy)ethylester,(+-)-henyl)-4-yl)methyl);1h-benzimidazole-7-carboxylicacid,2-ethoxy-1-((2’-(1h-tetrazol-5-yl)(1,1’-bip;tcv116;Candestartan;CandesartanCilexetil99.0%Min
CAS號: 145040-37-5
分子式: C33H34N6O6
分子量: 610.66
EINECS號: 
相關類別: 醫藥原料;中間體;Antihypertensive;API;APIs;Hypertension;Bases & Related Reagents;Intermediates & Fine Chemicals;Nucleotides;Pharmaceuticals;Candesartan;Heterocycles
Mol文件: 145040-37-5.mol
©2025 武漢康寶泰精細化工有限公司武昌一部 版權所有   技術支持:化工網   訪問量:17504  
 
主站蜘蛛池模板: | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |